Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.

Carmine CarboneGeny PiroAntonio AgostiniPietro DelfinoFrancesco De SanctisVincenzo NascaFrancesco SpallottaClaudio SetteMaurizio MartiniStefano UgelVincenzo CorboPaola CappelloEmilio BriaAldo ScarpaGiampaolo Tortora

Published in: Journal for immunotherapy of cancer (2022)

We demonstrated a potent antitumor activity of IMO-2125 and anti-PD1 combination in immunotherapy-resistant PDAC models through the modulation of immune microenvironment, providing the rationale to translate this strategy into a clinical setting.

Keyphrases

stem cells
toll like receptor
inflammatory response
immune response
clinical trial
ultrasound guided